Metabolic–dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson’s disease
暂无分享,去创建一个
Koen Van Laere | Guy Bormans | Veerle Baekelandt | Cindy Casteels | G. Bormans | K. Laere | C. Casteels | V. Baekelandt | Erwin Lauwers | E. Lauwers
[1] J. P. Huston,et al. UNILATERAL 6-HYDROXYDOPAMINE LESIONS OF MESO-STRIATAL DOPAMINE NEURONS AND THEIR PHYSIOLOGICAL SEQUELAE , 1996, Progress in Neurobiology.
[2] N. Wierup,et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.
[3] E. Broussolle,et al. Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease , 2001, Neurophysiologie Clinique/Clinical Neurophysiology.
[4] David Eidelberg,et al. Metabolic brain networks associated with cognitive function in Parkinson's disease , 2007, NeuroImage.
[5] R. Wurtman,et al. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization , 1980, Brain Research.
[6] M Samii,et al. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [18F]FDG‐PET , 2001, Movement disorders : official journal of the Movement Disorder Society.
[7] 稲次 基希. In vivo PET measurements with [11C]PE2I to evaluate fetal mesencephalic transplantations to unilateral 6-OHDA-lesioned rats , 2006 .
[8] Tetsuya Mori,et al. Gender differences in cerebral glucose metabolism: a PET study , 2002, Journal of the Neurological Sciences.
[9] T. Schallert,et al. Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism , 2000 .
[10] S. Houle,et al. In vivo evaluation of [11C]- and [18F]-labelled cocaine analogues as potential dopamine transporter ligands for positron emission tomography. , 1996, Nuclear medicine and biology.
[11] G. Di Chiara,et al. Local cerebral glucose utilization after D1 receptor stimulation in 6‐OHDA lesioned rats: Effect of sensitization (priming) with a dopaminergic agonist , 1993, Synapse.
[12] Patrik Brundin,et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice , 2005, Behavioural Brain Research.
[13] T. Ishikawa,et al. The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[14] Doris J. Doudet,et al. Evaluation of the Integrity of the Dopamine System in a Rodent Model of Parkinson’s Disease: Small Animal Positron Emission Tomography Compared to Behavioral Assessment and Autoradiography , 2006, Molecular Imaging and Biology.
[15] George Maeda,et al. Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats , 1999, Brain Research.
[16] J. P. Huston,et al. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.
[17] G. Cohen. Oxy-radical toxicity in catecholamine neurons. , 1984, Neurotoxicology.
[18] R. C. Collins,et al. Metabolic effects of unilateral lesion of the substantia nigra , 1981, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[19] David Blum,et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.
[20] K. Gwinn‐Hardy,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[21] Anna Barnes,et al. FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.
[22] Jean-Claude Baron,et al. Executive processes in Parkinson's disease: FDG‐PET and network analysis , 2004, Human brain mapping.
[23] Simon R. Cherry,et al. Deficits in Striatal Dopamine D2 Receptors and Energy Metabolism Detected by in Vivo MicroPET Imaging in a Rat Model of Huntington's Disease , 2000, Experimental Neurology.
[24] Z. Susel,et al. Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[25] S. Obayashi,et al. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats , 2005, Brain Research.
[26] Gerda Andringa,et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease , 2005, NeuroImage.
[27] R. Burke,et al. 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[28] O. Isacson,et al. Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging , 2002, The European journal of neuroscience.
[29] Johan Nuyts,et al. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] C. Patlak,et al. Pentobarbital produces dissimilar changes in glucose influx and utilization in brain. , 1991, The American journal of physiology.
[31] J. Rinne,et al. Uptake of 6‐[18F]fluoro‐L‐dopa and [18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease , 2004, Synapse.
[32] V. Dhawan,et al. Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.
[33] John R. Votaw,et al. Isoflurane Alters the Amount of Dopamine Transporter Expressed on the Plasma Membrane in Humans , 2004, Anesthesiology.
[34] Y. Magata,et al. Alteration of striatal [11C]raclopride and 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine uptake precedes development of methamphetamine-induced rotation following unilateral 6-hydroxydopamine lesions of medial forebrain bundle in rats , 2005, Neuroscience Letters.
[35] A. Dagher,et al. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. , 2001, Brain : a journal of neurology.
[36] V. Sturm,et al. Subthalamic Nucleus Stimulation Restores Glucose Metabolism in Associative and Limbic Cortices and in Cerebellum: Evidence from a FDG-PET Study in Advanced Parkinson's Disease , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[37] Jae Seung Kim. Metabolic Topography of Parkinsonism , 2007 .
[38] Klaus Wienhard,et al. Measurement of glucose consumption using [(18)F]fluorodeoxyglucose. , 2002, Methods.
[39] C. Verney,et al. Mesolimbic dopaminergic neurons innervating the hippocampal formation in the rat: a combined retrograde tracing and immunohistochemical study , 1994, Brain Research.
[40] D E Kuhl,et al. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method , 1984, Annals of neurology.
[41] D. Guilloteau,et al. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease , 1999, Synapse.
[42] Jesper L. R. Andersson,et al. A template for spatial normalisation of MR images of the rat brain , 2003, Journal of Neuroscience Methods.